Sort
15,273 grants matching “antimicrobial resistance”
Feature Learning For Improved Multiplex Disease Diagnosis
$189,594Erik J Nilsson · Deurion, Llc · R43 · FY2018 · GM
Macrophages and Resistance to Mycobacterium Tuberculosis Infection in Humans
$189,540Jason Simmons · University Of Washington · K08 · FY2023 · AI
Towards the Development of Engineered Phage Therapeutics against MDR Pathogens
$189,526Elena M Barbu · Synthetic Genomics Vaccines, Inc. · R21 · FY2017 · AI
Impact of unsaturated fatty acids on S. aureus membrane properties.
$189,445Brian James Wilkinson · Illinois State University · R21 · FY2018 · AI
Antimicrobial Resistance and Therapeutic Discovery Training Program
$189,437William Maurice Shafer · Emory University · T32 · FY2017 · AI
Predicting Resistance: Validating Mathematical Models
$189,375University Of California San Francisco · R21 · FY2003 · AI
Predicting Resistance: Validating Mathematical Models
$189,375University Of California San Francisco · R21 · FY2004 · AI
Basis of MyD88-independent Th1 immunity during Toxoplasma infection
$189,375Eric Y Denkers · University Of New Mexico · R21 · FY2017 · AI
Identification of novel DNA repair mechanisms in Mycobacterium tuberculosis
$189,375Pallavi Ghosh · University Of Pittsburgh At Pittsburgh · R21 · FY2012 · AI
A novel antimicrobial resistance mechanism for Borrelia burgdorferi
$189,375Jonathan T Skare · Texas A&M University Health Science Ctr · R21 · FY2023 · AI
Elucidating the Nexus Between Urinary Tract Infection and Diabetes
$189,375Sargurunathan Subashchandrabose · Texas A&M Agrilife Research · R21 · FY2023 · AI
The developing intestinal immune system in Yersinia enterocolitica infection
$189,338Rebecca D Adkins · University Of Miami School Of Medicine · R21 · FY2010 · AI
Metal withholding responses in the gut mucosa
$189,338Manuela Raffatellu · University Of California-Irvine · R21 · FY2010 · AI
Class 1 Histone Deacetylases Regulate Innate Immune Resistance to Mycobacterium tuberculosis Infection
$189,324Monica Campo Patino · University Of Washington · K08 · FY2019 · AI
Class 1 Histone Deacetylases Regulate Innate Immune Resistance to Mycobacterium tuberculosis Infection
$189,324Monica Campo Patino · University Of Washington · K08 · FY2020 · AI
Class 1 Histone Deacetylases Regulate Innate Immune Resistance to Mycobacterium tuberculosis Infection
$189,324Monica Campo Patino · University Of Minnesota · K08 · FY2022 · AI
PAS domain and redox regulation of the S. aureus SrrB sensor histidine kinase
$189,318Ernesto Jorge Fuentes · University Of Iowa · R21 · FY2019 · AI
Procuring Native Natural Product Producers by In Situ Chimera Assembly
$189,250Robert Henry Cichewicz · University Of Oklahoma · R21 · FY2016 · AI
Targeted Macromolecular Antimicrobial Prodrugs Against Pseudomonas Aeruginosa
$189,240Christopher Akinleye Alabi · Cornell University · R21 · FY2020 · AI
Mechanisms of Pseudomonas aeruginosa adaptation, colonization, and host responses in children with artificial airways
$189,146Glenn J Rapsinski · University Of Pittsburgh At Pittsburgh · K08 · FY2025 · AI
A novel mechanism of rifamycin resistance in Mycobacterium abscessus mediated by a putative helicase
$189,135Pallavi Ghosh · Wadsworth Center · R21 · FY2022 · AI
Development of Staphylococcalcidal Human Peptides
$189,099William Maurice Shafer · Emory University · R01 · FY2006 · AI
BACTERIOPHAGES (PHAGES) ARE BEING CONSIDERED AS AN ALTERNATIVE TOOL TO ANTIMICROBIAL DRUGS FOR TREATING BACTERIAL INFECTIONS IN MAN AND ANIMALS. OF DISEASES AFFECTING CATTLE IN THE U.S. BEEF FEEDLOT PRODUCTION SYSTEMS, LIVER ABSCESSES CAUSED BY FUSOBACTERIUM NECROPHORUM SUBSP. NECROPHORUM ARE A SIGNIFICANT CONCERN FOR ANIMAL HEALTH AND WELFARE AND PRODUCTION ECONOMICS. AVAILABLE EFFICACIOUS TREATMENTS ARE LIMITED TO ANTIMICROBIAL DRUGS, CURRENTLY THE MACROLIDE TYLOSIN AND TETRACYCLINES. MACROLIDES ARE RANKED BY THE WORLD HEALTH ORGANIZATION AS CRITICALLY IMPORTANT FOR HUMAN THERAPEUTIC OPTIONS AND WITH HIGHEST RISKS OF BACTERIAL RESISTANCE. AN EFFICACIOUS AND ECONOMICALLY SOUND ALTERNATIVE TO TYLOSIN COULD ENABLE THE INDUSTRY TO REDUCE OR ELIMINATE USE OF THIS CRITICALLY IMPORTANT DRUG CLASS, WHILE STILL ENSURING CATTLE HEALTH AND WELFARE. THIS PATHOGEN IS AN ANAEROBIC BACTERIAL SUBSP., AND PHAGES OF ANAEROBIC BACTERIA HAVE BEEN STUDIED THE LEAST. WHILE THERE ARE REPORTS OF ISOLATIONOF PHAGES OF F. NECROPHORUM FROM CATTLE RUMEN FLUIDS AND CITY SEWAGE IN OTHER COUNTRIES, EFFICACY OF THE PHAGES FOR PREVENTING OR REDUCING LIVER ABSCESSES CAUSED BY THE PATHOGEN HAS NOT BEEN STUDIED. IN THIS PROJECT, FREQUENCY OF ISOLATION OF PHAGES OF F. NECROPHORUM FROM RUMEN FLUIDS OF BEEF FEEDLOT CATTLE RAISED IN THE U.S. WILL BE ESTIMATED. THE PHAGES WILL BE DESCRIBED IN TERMS OF THEIR TAXONOMY, GENOMIC COMPOSITION, AND PATHOGEN STRAIN HOST-RANGE. AS WELL, DISTRIBUTION OF THE PHAGES IN A MAMMALIAN HOST AND THEIR POTENTIAL TO PREVENT OR REDUCE LIVER ABSCESSES CAUSED BY F. NECROPHORUM WILL BE TESTED IN A MOUSE MODEL OF THE DISEASE. THESE PROOF-OF-CONCEPT STUDIES WILL PROVIDE AN EVALUATION OF PHAGES AS AN ALTERNATIVE TOOL TO ANTIMICROBIAL DRUGS FOR THE DISEASE CONTROL. SUCH AN ALTERNATIVE WOULD SUPPORT LONG-TERM INDUSTRY SUSTAINABILITY AND CONTRIBUTE TO WIDER SOCIETAL EFFORTS TO PREVENT ANTIMICROBIAL RESISTANCE IN BACTERIAL PATHOGENS OF MAN AND ANIMALS.
$189,045Kansas State University · · FY2019 · National Institute of Food and Agriculture
Synthetic mucus for local therapeutic delivery
$188,947Gregg Duncan · Univ Of Maryland, College Park · R21 · FY2022 · EB
Stenotrophomonas Maltophilia Type IV Secretion: Modulator of Both Host-Cell Apoptosis and Interbacterial Killing
$188,839Nicholas Philip Cianciotto · Northwestern University At Chicago · R21 · FY2020 · AI